Clinical trials: Glaucoma,Open-Angle
Glaucoma, Ocular Hypertension
Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)
The purpose of this study was to assess efficacy and tolerability of travoprost 0.004% vs. bimatoprost 0.01% during the after office hour period (4 pm to 8 pm) in subjects with open-angle glaucoma or ocular hypertension after 6…
- Conditions
- Glaucoma, Ocular Hypertension, Open-Angle Glaucoma
- Trial name
- NCT01464424
- Testing
- Travoprost 0.004% ophthalmic solution, Bimatoprost 0.01% ophthalmic solution
- Volunteers
- 84 people
- Sponsor
- Alcon Research
Ocular Hypertension, Open Angle Glaucoma
Study of INS115644 Ophthalmic Solution in Subjects With Ocular Hypertension or Glaucoma
The purpose of this trial is to evaluate the safety and tolerability of INS115644 Ophthalmic Solution in subjects with bilateral ocular hypertension or early primary open angle glaucoma and to investigate the intraocular pressure…
- Trial name
- NCT00443924
- Testing
- INS115644 Ophthalmic Solution
- Volunteers
- 56 people
- Sponsor
- Merck Sharp & Dohme LLC
Neovascular Age Related Macular Degeneration (AMD), Open Angle Glaucoma
TF (SENSIMED Triggerfish) in Intraocular Anti-VEGF (Vascular Endothelial Growth Factor) Injection
This is a prospective, open label study assessing the 24-hour IOP patterns using TF in patients undergoing anti-VEGF injection for the treatment of neovascular AMD (age related macular degeneration).
- Trial name
- NCT01983579
- Testing
- Intraocular anti-VEGF injection, SENSIMED Triggerfish
- Where
- Spain
- Volunteers
- 4 people
- Sponsor
- Sensimed AG
Primary Open Angle Glaucoma, Ocular Hypertension
Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
Reduction of elevated pressure in the eye (Intraocular pressure, or 'IOP') with eye drop medications has been shown to be effective in delaying or preventing the progression of glaucoma, and it is the only proven method for…
- Trial name
- ANGEL-2 (NCT04742283)
- Testing
- DE-126 Ophthalmic Solution 0.002% QD, Timolol Maleate Ophthalmic Solution 0.5% BID
- Where
- 41 sites in United States
- Volunteers
- 323 people
- Sponsor
- Santen Inc.
Primary Open Angle Glaucoma, Ocular Hypertension
A Clinical Study to Evaluate the Efficacy and Safety of CKD-351
The purpose of this study is to evaluate efficacy and safety of CKD-351
- Trial name
- NCT04448223
- Testing
- CKD-351, Latanoprost+Dorzolmamide
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Glaucoma, Open-Angle, Ocular Hypertension
Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
This is an observational study of Lumigan® 0.01% (bimatoprost) treatment in clinical practice for patients with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
- Trial name
- NCT01628588
- Testing
- bimatoprost 0.01%
- Where
- Netherlands
- Volunteers
- 854 people
- Sponsor
- Allergan
Primary Open Angle Glaucoma, Cataract
A Study of the Helix Surgical System in Primary Open-Angle Glaucoma (POAG) and Cataract (HELIX)
A study to assess the safety of the Helix Surgical System in cataract surgery and to gain early evidence of its effectiveness in lowering intraocular pressure (IOP) in subjects with mild to moderate primary open-angle glaucoma…
- Trial name
- HELIX (NCT06948773)
- Testing
- Helix Surgical System
- Where
- Panama
- Volunteers
- 25 people
- Sponsor
- Sight Sciences, Inc.
Open-Angle Glaucoma, Ocular Hypertension
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension
This study evaluates the duration of intraocular pressure (IOP)-lowering effect and safety of as needed administrations of Bimatoprost sustained release (SR) in participants with open-angle glaucoma (OAG) or ocular hypertension…
- Trial name
- TRITON (NCT03850782)
- Testing
- Bimatoprost (SR)
- Where
- 108 sites in United States, Argentina and 14 more
- Volunteers
- 515 people
- Sponsor
- AbbVie
Glaucoma
Evaluate the Efficacy and Safety of Glaucoma Implant in Primary Open Angle Glaucoma
The objective of this study is to evaluate the efficacy and safety of glaucoma device in the treatment of primary open-angle glaucoma.
- Trial name
- NCT05892185
- Testing
- GELA, XEN
- Volunteers
- 20 people
- Sponsor
- Mingche Biotechnology CO., LTD
Open-Angle Glaucoma
A Study of the Glaukos Trabecular Micro-Bypass Stent in Refractory Open Angle Glaucoma Subjects
The purpose of this study is to evaluate the safety and efficacy of the iStent trabecular micro-bypass stent in reducing intraocular pressure (IOP) in refractory open-angle glaucoma subjects.
- Trial name
- NCT00326040
- Testing
- Glaucoma Surgery
- Where
- 7 sites in Germany, Italy and 2 more
- Volunteers
- 45 people
- Sponsor
- Glaukos Corporation
Primary Open-angle Glaucoma, Ocular Hypertension
Levobetaxolol Hydrochloride Eye Drops for Treatment of Primary Open-angle Glaucoma or Ocular Hypertension
To evaluate the safety and efficacy of Levobetaxolol in Chinese patients with glaucoma.
- Trial name
- NCT02617459
- Testing
- Levobetaxolol eye drops, Betaxolol eye drops
- Where
- China
- Volunteers
- 366 people
- Sponsor
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Glaucoma, Open-Angle
Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated
This study will evaluate the safety and efficacy of bimatoprost/timolol fixed combination (GANfort®) versus latanoprost (Xalatan®) in patients with open-angle glaucoma who have never been previously treated and are at high risk…
- Trial name
- NCT01243567
- Testing
- bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution, latanoprost 0.005% ophthalmic solution
- Where
- 2 sites in Portugal, Spain
- Volunteers
- 81 people
- Sponsor
- Allergan
Glaucoma, Open-angle, Ocular Hypertension
A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to evaluate the intraocular pressure(IOP)-lowering efficacy of a combination IOP-lowering therapy in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00311389
- Testing
- Travoprost 0.004%/Timolol maleate 0.5% ophthalmic solution, Latanoprost 0.005%/Timolol 0.005% ophthalmic solution
- Where
- Belgium
- Volunteers
- 408 people
- Sponsor
- Alcon Research
Primary Open-Angle Glaucoma, Ocular Hypertension
An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert
This study evaluated the long-term (9-months) safety of the Bimatoprost Ocular Insert in participants with Glaucoma or Ocular Hypertension who completed study FSV5-004.
- Trial name
- OLE2 (NCT02537015)
- Testing
- Bimatoprost
- Where
- 9 sites in United States
- Volunteers
- 81 people
- Sponsor
- ForSight Vision5, Inc.
Open Angle Glaucoma (OAG)
Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma
A Prospective, Multicenter, Single-Arm, Open-Label Clinical Trial
- Trial name
- NCT07220876
- Testing
- VisiPlate Glaucoma Implant
- Where
- 14 sites in United States, South Africa
- Volunteers
- 165 people
- Sponsor
- Avisi Technologies Inc.
Glaucoma, Primary Open Angle (POAG), Ocular Hypertension
Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure
To determine the predictive factors of a positive response to latanoprost 0.005% / timolol 0.5% fixed combination (defined as a 10% IOP reduction from baseline), after 12 weeks of treatment (age, sex, ethnic origin, patient's…
- Trial name
- PREDICOM (NCT00230763)
- Testing
- GSS questionnaire, IOP, LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION
- Where
- 102 sites in France
- Volunteers
- 396 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Open Angle Glaucoma, Ocular Hypertension
Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients
The objective of the study is to assess the efficacy and safety of T2347 (Latanoprost 0.005% + Timolol 0.5% unpreserved eye drops) versus Xalacom® in ocular hypertensive or glaucomatous patients initially treated, stabilised by…
- Trial name
- NCT02278614
- Testing
- T2347, Xalacom
- Where
- France
- Volunteers
- 242 people
- Sponsor
- Laboratoires Thea
Glaucoma
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
The purpose of the study is to assess the safety, tolerability, and IOP effects of RO5093151 following 7 days of topical ocular treatment in patients with primary open angle glaucoma or ocular hypertension.
- Trial name
- NCT02622334
- Testing
- Latanoprost, RO5093151
- Where
- 7 sites in United States, Singapore
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Glaucoma, Open-Angle
A Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System
The purpose of this study is to evaluate the long-term safety and effectiveness of the OMNI® Surgical System in subjects who were treated under protocol #06213
- Trial name
- NCT05044793
- Testing
- OMNI® Surgical System
- Where
- 4 sites in United States
- Volunteers
- 70 people
- Sponsor
- Sight Sciences, Inc.
Glaucoma, Open-Angle, Ocular Hypertension
Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension
This study will evaluate the intraocular pressure (IOP)-lowering effect and safety of bimatoprost SR compared with selective laser trabeculoplasty in patients with open-angle glaucoma or ocular hypertension who are not adequately…
- Trial name
- NCT02507687
- Testing
- Bimatoprost SR, Selective Laser Trabeculoplasty
- Where
- 95 sites in United States, Australia and 10 more
- Volunteers
- 240 people
- Sponsor
- AbbVie